Ensysce Biosciences, Inc. (ENSC): Nasdaq/NYSE listing notice — Nasdaq notifies Ensysce of delisting risk for equity shortfall

Ensysce Biosciences, Inc.

Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.
Must submit a plan by July 6, 2026 (45 days) to regain compliance; if accepted, extension up to 180 days from May 21.
Company plans to submit a timely plan and explore options, but no assurance Nasdaq will accept or extension granted.
Failure could lead to delisting; company may appeal to Nasdaq Hearings Panel if plan rejected.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 21, 2026, Ensysce Biosciences Inc. (the “ Company ”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that due to the Company’s non-compliance with the $2

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-025061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.